July 12, 2024 Project ECHO® Dementia Didactic:
UW Project ECHO Dementia Recording for July 12: Amyloid Monoclonal Antibodies
Recording TBA
Resources
- van Dyck, Christopher H et al. “Lecanemab in Early Alzheimer's Disease” The New England journal of medicine vol. 388,1 (2023): 9-21. doi:10.1056/NEJMoa2212948
- Rosenbloom, Michael H et al. “A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's Disease.” CNS drugs vol. 38,7 (2024): 493-505. doi:10.1007/s40263-024-01097-w
- Cummings, J et al. “Lecanemab: Appropriate Use Recommendations.” The journal of prevention of Alzheimer's disease vol. 10,3 (2023): 362-377. doi:10.14283/jpad.2023.30
- Advisory Panel of Experts Endorses F.D.A Approval of New Alzheimer's Drug - NY Times Article June 2024
- Sims, John R et al. “Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.” JAMA vol. 330,6 (2023): 512-527. doi:10.1001/jama.2023.13239
- Schindler, Suzanne E et al. “Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.” Nature reviews. Neurology vol. 20,7 (2024): 426-439. doi:10.1038/s41582-024-00977-5